A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Identifieur interne : 000A04 ( PubMed/Curation ); précédent : 000A03; suivant : 000A05A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Auteurs : Tian-Tian Yao [République populaire de Chine] ; Jian-Dan Qian [République populaire de Chine] ; Wen-Yan Zhu [République populaire de Chine] ; Yan Wang [République populaire de Chine] ; Gui-Qiang Wang [République populaire de Chine]Source :
- Journal of medical virology [ 1096-9071 ] ; 2020.
Abstract
In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.
DOI: 10.1002/jmv.25729
PubMed: 32104907
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A04
Links to Exploration step
pubmed:32104907Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.</title><author><name sortKey="Yao, Tian Tian" sort="Yao, Tian Tian" uniqKey="Yao T" first="Tian-Tian" last="Yao">Tian-Tian Yao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Qian, Jian Dan" sort="Qian, Jian Dan" uniqKey="Qian J" first="Jian-Dan" last="Qian">Jian-Dan Qian</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Zhu, Wen Yan" sort="Zhu, Wen Yan" uniqKey="Zhu W" first="Wen-Yan" last="Zhu">Wen-Yan Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Yan" sort="Wang, Yan" uniqKey="Wang Y" first="Yan" last="Wang">Yan Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Gui Qiang" sort="Wang, Gui Qiang" uniqKey="Wang G" first="Gui-Qiang" last="Wang">Gui-Qiang Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32104907</idno><idno type="pmid">32104907</idno><idno type="doi">10.1002/jmv.25729</idno><idno type="wicri:Area/PubMed/Corpus">000A04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A04</idno><idno type="wicri:Area/PubMed/Curation">000A04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.</title><author><name sortKey="Yao, Tian Tian" sort="Yao, Tian Tian" uniqKey="Yao T" first="Tian-Tian" last="Yao">Tian-Tian Yao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Qian, Jian Dan" sort="Qian, Jian Dan" uniqKey="Qian J" first="Jian-Dan" last="Qian">Jian-Dan Qian</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Zhu, Wen Yan" sort="Zhu, Wen Yan" uniqKey="Zhu W" first="Wen-Yan" last="Zhu">Wen-Yan Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Yan" sort="Wang, Yan" uniqKey="Wang Y" first="Yan" last="Wang">Yan Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Wang, Gui Qiang" sort="Wang, Gui Qiang" uniqKey="Wang G" first="Gui-Qiang" last="Wang">Gui-Qiang Wang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of medical virology</title><idno type="eISSN">1096-9071</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32104907</PMID><DateRevised><Year>2020</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J. Med. Virol.</ISOAbbreviation></Journal><ArticleTitle>A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.25729</ELocationID><Abstract><AbstractText>In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID-19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID-19.</AbstractText><CopyrightInformation>© 2020 The Authors. Journal of Medical Virology published by Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Tian-Tian</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Jian-Dan</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Wen-Yan</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gui-Qiang</ForeName><Initials>GQ</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-0515-7974</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases and the Center for Liver Diseases, Peking University First Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, Zhejiang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking University International Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81870417</GrantID><Agency>National Natural Science Foundation of China</Agency><Country></Country></Grant><Grant><GrantID>2018SF049</GrantID><Agency>Scientific Research Seed Fund of Peking University First Hospital</Agency><Country></Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">MERS</Keyword><Keyword MajorTopicYN="N">SARS</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">lopinavir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32104907</ArticleId><ArticleId IdType="doi">10.1002/jmv.25729</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003;8(suppl):S9-S14.</Citation></Reference><Reference><Citation>Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-1820.</Citation></Reference><Reference><Citation>World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/. Accessed.</Citation></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020. https://doi.org/10.1038/s41586-020-2012-7</Citation></Reference><Reference><Citation>Hurst M, Faulds D. Lopinavir. Drugs. 2000;60(6):1380-1381.</Citation></Reference><Reference><Citation>de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875-4884.</Citation></Reference><Reference><Citation>Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.</Citation></Reference><Reference><Citation>Boffito M, Arnaudo I, Raiteri R, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS. 2002;16(15):2081-2083.</Citation></Reference><Reference><Citation>Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors. J Theor Biol. 2008;254(4):861-867.</Citation></Reference><Reference><Citation>Zhang XW, Yap YL. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem. 2004;12(10):2517-2521.</Citation></Reference><Reference><Citation>Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719-725.</Citation></Reference><Reference><Citation>Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69-75.</Citation></Reference><Reference><Citation>Chu CM, Cheng VC, Hung IF, et al. Group HUSS. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-256.</Citation></Reference><Reference><Citation>Martina BE, Haagmans BL, Kuiken T, et al. Virology: SARS virus infection of cats and ferrets. Nature. 2003;425(6961):915.</Citation></Reference><Reference><Citation>Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606-616.</Citation></Reference><Reference><Citation>Chan JF, Yao Y, Yeung ML, et al. Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904-1913.</Citation></Reference><Reference><Citation>Vastag B. Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS. JAMA. 2003;290(13):1695-1696.</Citation></Reference><Reference><Citation>Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399-406.</Citation></Reference><Reference><Citation>Peiris JS, Chu CM, Cheng VC, et al. Group HUSS. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361(9371):1767-1772.</Citation></Reference><Reference><Citation>Spanakis N, Tsiodras S, Haagmans BL, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents. 2014;44(6):528-532.</Citation></Reference><Reference><Citation>Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455-459.</Citation></Reference><Reference><Citation>Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infect. 2019;101(1):42-46.</Citation></Reference><Reference><Citation>Chong YP, Song JY, Seo YB, Choi JP, Shin HS, Rapid Response T. Antiviral treatment guidelines for Middle East respiratory syndrome. Infect Chemother. 2015;47(3):212-222.</Citation></Reference><Reference><Citation>Arabi YM, Asiri AY, Assiri AM, et al. the Saudi Critical Care Trials g. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-beta1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020;21(1):8.</Citation></Reference><Reference><Citation>Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020. https://doi.org/10.5582/bst.2020.01030</Citation></Reference><Reference><Citation>Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 novel coronavirus. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E002.</Citation></Reference><Reference><Citation>Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020. https://doi.org/10.5582/bst.2020.01020</Citation></Reference><Reference><Citation>Chen J, Ling Y, Xi XH, et al. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chin J Infect Dis. 2020;38(0):E008.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000A04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32104907
|texte= A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32104907" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |